Year: 2018
Type: article
Abstract: Gastric adenocarcinoma (GAC) is estimated as the fifteenth most common cancer in the USA. Incidence rate has been gradually decreasing, but prognosis remains dismal. For patients with locally advanced GAC (stage > T1B and < T4B), multimodality therapies, such as surgery, chemotherapy, and radiation therapy, are needed. Perioperative chemotherapy or postoperative chemoradiation/chemotherapy is recommended. For metastatic GAC patients, combination of two cytotoxics (platinum compound and fluoropyrimidine) has become a common place in the USA, and when HER2 is positive, trastuzumab is added. When GAC progresses after the first line therapy, additional biomarkers (microsatellite instability and programmed death ligand 1) should be tested so that checkpoint inhibitors can be used. Overall, the options for advanced GAC patients are limited and more research is needed.
Authors: Kazuto Harada, Hideo Baba, Jaffer A. Ajani
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G1655421535, G1677944058, Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha, Molecular Markers of Response to Chemoradiation in Localized Esophageal Cancer, G451806386, G5208572710, G5313212532, G6077205801, G7623734931, G7659053506, Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer, Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction, G8705956310
OpenAlex ID: W2801675843